ES2084129T3 - Nuevas calconas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. - Google Patents

Nuevas calconas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.

Info

Publication number
ES2084129T3
ES2084129T3 ES91401679T ES91401679T ES2084129T3 ES 2084129 T3 ES2084129 T3 ES 2084129T3 ES 91401679 T ES91401679 T ES 91401679T ES 91401679 T ES91401679 T ES 91401679T ES 2084129 T3 ES2084129 T3 ES 2084129T3
Authority
ES
Spain
Prior art keywords
group
hydrogen atom
cirf
lower alkyl
case
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91401679T
Other languages
English (en)
Inventor
Daniel Lesieur
Daniel-Henri Caignard
Isabelle Lesieur
Michelle Devissaguet
Beatrice Guardiola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Servier de Medecine Translationnelle SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2084129T3 publication Critical patent/ES2084129T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS ANTIINFLAMATORIOS Y ANTIOXIDANTES DE FORMULA (I): EN LA QUE: R SUB 1 REPRESENTA UN ATOMO DE HIDROGENO O UN RADICAL ALQUILO INFERIOR, X REPRESENTA: . UN ATOMO DE OXIGENO O DE AZUFRE, . UN GRUPO CH SUB 2 SIEMPRE QUE EN ESTE CASO Y REPRESENTE UN ATOMO DE OXIGENO O DE AZUFRE, Y REPRESENTA: . UN ENLACE SIMPLE O UN GRUPO CR SUB 7 R SUB 8 DONDE R SUB 7 Y R SUB 8 IDENTICOS O DIFERENTES REPRESENTAN INDEPENDIENTEMENTE UNO DE OTRO UN ATOMO DE HIDROGENO, UN GRUPO ALQUILO INFERIOR, UN GRUPO FENILO, UN GRUPO FENILO SUSTITUIDO, UN GRUPO FENIL ALQUILO O UN GRUPO FENIL ALQUILO SUSTITUIDO, . UN ATOMO DE OXIGENO O DE AZUFRE SIEMPRE QUE EN ESTE CASO X REPRESENTE UN GRUPO CH SUB 2, Z REPRESENTA O BIEN UN ATOMO DE HIDROGENO Y EN ESTE CASO X REPRESENTA UN GRUPO CH SUB 2, DE HIDROGENO O BIEN Z FORMA CON T UN ESLABON '') CON N NUMERO ENTERO IGUAL A 0, 1, 2 O 3 ENTENDIENDOSE QUE EN ESTE CASO Z ES LLEVADO POR UN CARBONO CERCANO DEL CARBONO PORTADOR DEL GRUPO ACILADO, Y E O E'' REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO ALQUILO INFERIOR, UN GRUPO FENILO, HETEROARILO, O FENILO SUSTITUIDO O HETEROARILO SUSTITUIDO. R SUB 2, R SUB 3 Y R SUB 4 IDENTICOS O DIFERENTES REPRESENTAN INDEPENDIENTEMENTE UNO DEL OTRO UN GRUPO HIDROXI O ALCOXI INFERIOR O UN GRUPO ALQUILO INFERIOR.
ES91401679T 1990-06-22 1991-06-21 Nuevas calconas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen. Expired - Lifetime ES2084129T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR909007813A FR2663633B1 (fr) 1990-06-22 1990-06-22 Nouvelles chalcones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
ES2084129T3 true ES2084129T3 (es) 1996-05-01

Family

ID=9397889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91401679T Expired - Lifetime ES2084129T3 (es) 1990-06-22 1991-06-21 Nuevas calconas heterociclicas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.

Country Status (16)

Country Link
US (1) US5179091A (es)
EP (1) EP0463945B1 (es)
JP (1) JPH0730054B2 (es)
AT (1) ATE132144T1 (es)
AU (1) AU631743B2 (es)
CA (1) CA2045256A1 (es)
DE (1) DE69115768T2 (es)
DK (1) DK0463945T3 (es)
ES (1) ES2084129T3 (es)
FR (1) FR2663633B1 (es)
GR (1) GR3019019T3 (es)
IE (1) IE912145A1 (es)
NZ (1) NZ238647A (es)
OA (1) OA09504A (es)
PT (1) PT98068A (es)
ZA (1) ZA914802B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084997A1 (en) * 1991-04-10 1992-10-11 Koji Kobayashi Oxazinone derivative
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
WO1999047118A1 (en) * 1998-03-16 1999-09-23 The Procter & Gamble Company Compositions for regulating skin appearance
EP1063967B1 (en) 1998-03-16 2004-02-11 The Procter & Gamble Company Compositions for regulating skin appearance
US8106094B2 (en) * 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) * 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US6750229B2 (en) 1998-07-06 2004-06-15 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin pigmentation
US20020197244A1 (en) * 1998-12-07 2002-12-26 Miri Seiberg Compositions and methods for regulating phagocytosis and ICAM-1 expression
US7985404B1 (en) * 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
US20040192669A1 (en) * 2000-04-13 2004-09-30 Rosenfeld Mark J. Novel compounds for use in weight loss and appetite suppression in humans
US7794761B2 (en) * 2000-04-13 2010-09-14 Seroctin Research & Technology, Inc. Methods for inducing anti-anxiety and calming effects in animals and humans
US8431550B2 (en) * 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) * 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US6555143B2 (en) 2001-02-28 2003-04-29 Johnson & Johnson Consumer Products, Inc. Legume products
CN1596240A (zh) * 2001-12-19 2005-03-16 阿特罗吉尼克斯公司 查耳酮衍生物及其治疗疾病的用途
US20030224075A1 (en) * 2002-02-21 2003-12-04 Jue-Chen Liu Soy composition for balancing combination skin
US20050004561A1 (en) * 2003-07-01 2005-01-06 Lynn Halas Method for removing hair
EP1677748A1 (en) * 2003-10-29 2006-07-12 Johnson & Johnson Consumer France SAS Compositions comprising soy products and dioic acids
US7524877B2 (en) 2003-11-20 2009-04-28 Seroctin Research & Technology, Inc. Compounds for use in weight loss and appetite suppression in humans
US20080008818A1 (en) * 2006-06-23 2008-01-10 Miri Seiberg Partially denatured whole soybean extracts and methods of use thereof
US20080089960A1 (en) * 2006-10-16 2008-04-17 Miri Seiberg Use of Legume Products for the Treatment and Prevention of Radiotherapy-Induced Skin Damage
CN103360338B (zh) * 2013-07-30 2015-04-01 中国科学院新疆理化技术研究所 一种查尔酮苯并噻唑酰胺类衍生物的制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2244506B1 (es) * 1973-06-26 1977-02-25 Inst Nat Sante Rech Med
FR2244507A1 (en) * 1973-06-26 1975-04-18 Inst Nat Sante Rech Med Chalcones and analogues - analgesics having low toxicity
FR2588868B1 (fr) * 1985-10-21 1988-11-10 Negma Laboratoires Acyl-7 benzoxazinones et leurs derives, procede pour les obtenir et compositions pharmaceutiques les contenant
FR2646350B1 (fr) * 1989-04-28 1991-06-28 Adir Nouveaux derives benzothiazolinoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
AU7917291A (en) 1992-01-02
EP0463945A1 (fr) 1992-01-02
FR2663633A1 (fr) 1991-12-27
IE912145A1 (en) 1992-01-01
JPH04230273A (ja) 1992-08-19
AU631743B2 (en) 1992-12-03
DE69115768D1 (de) 1996-02-08
JPH0730054B2 (ja) 1995-04-05
EP0463945B1 (fr) 1995-12-27
OA09504A (fr) 1992-11-15
CA2045256A1 (fr) 1991-12-23
US5179091A (en) 1993-01-12
ATE132144T1 (de) 1996-01-15
NZ238647A (en) 1992-08-26
ZA914802B (en) 1992-04-29
FR2663633B1 (fr) 1994-06-17
GR3019019T3 (en) 1996-05-31
PT98068A (pt) 1992-03-31
DK0463945T3 (da) 1996-04-29
DE69115768T2 (de) 1996-08-08

Similar Documents

Publication Publication Date Title
AU631743B2 (en) New chalcones, process for preparing these and pharmaceutical compositions containing them
DE58908652D1 (de) Aminoalkylindole, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate.
SE8104783L (sv) Heterocykliska foreningar
NZ218243A (en) B-carboline derivatives and pharmaceutical compositions
DK359387D0 (da) Oploesninger af oxazaphosphoriner med forbedret stabilitet og fremgangsmaade til deres fremstilling
ES2060970T3 (es) Nuevos derivados de benzonaftiridina-1,8, su preparacion y las composiciones que les contienen.
ES471245A1 (es) Un procedimiento para la preparacion de una composicion her-bicida a base de derivados de n'-fenil-n-metilurea
ES2057802T3 (es) Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen.
SE8006953L (sv) Heterocykliska foreningar
MX170732B (es) Composicion de derivados de succinimida y su uso
FI910924A0 (fi) Nya propanaminer, framstaellning av dessa och anvaendning av dessa foer terapeutiska aendamaol, i synnerhet som diarremediciner.
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
SE8504346L (sv) N-alkyl(en)-n-(o,o-disubstituerad tiofosforyl)-n',n'-disubstituerade glycinamider, sett att framstella dessa samt akaricid, insekticid och fungicid, innehallande dess foreningar som verksam bestandsdel
ES2063157T3 (es) Nuevos derivados del indol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES8400406A1 (es) Procedimiento para preparar derivados de indano.
ATE19879T1 (de) Furyloxazolylessigsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IT1215587B (it) Derivati della 1-benzoil2-oxo 5-alcossi pirrolidina, loro procedimento di preparazione e loro impiego come sostanza medicinale.
ES520486A0 (es) Procedimiento para la preparacion de fenoleteres biciclicos.
ES2052206T3 (es) Procedimiento de preparacion de nuevos derivados de benzotiazolinona y las composiciones farmaceuticas que los contienen.
ATE90086T1 (de) Phenothiazinderivate, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DE3270999D1 (de) N-substituted-tetrahydroisophthalimide derivatives
SE7909980L (sv) I-amino-indolin-derivat, deras framstellning och farmaceutiska kompositioner innehallande desamma
GB2022583A (en) New ionic polyiodo benzene derivatives useful as X-ray contrast media
AU8292787A (en) Fluorine-containing macrolide compounds and their use
SE7905862L (sv) Substituerade 4-aryl-2,5-dihydro-furan-2-oner och 4-aryl-1,5-dihydro-2h-pyrrol-2-oner och sett for deras framstellning

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 463945

Country of ref document: ES